Opinion|Videos|January 31, 2024
Key Considerations in Managing Hypertension Risk with BTKis in CLL
Amber Koehler, PA-C, provides expert perspective on addressing hypertension risk in CLL patients undergoing treatment with BTK inhibitors.
Advertisement
Episodes in this series
Advertisement
Related to this article
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
2
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5